← All trials
NCT05656027
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2022
- Primary completion
- Nov 1, 2023
- Completion date
- Dec 20, 2023
- First posted
- Dec 19, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 435
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Presbyopia Therapies, LLCLead sponsor
- ORA, Inc.Collaborator
- Presbyopia Therapies, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.